Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Full description

Saved in:
Bibliographic Details
Main Authors: Olga S. Blomberg, Kevin Kos, Lorenzo Spagnuolo, Olga I. Isaeva, Hannah Garner, Max D. Wellenstein, Noor Bakker, Danique E.M. Duits, Kelly Kersten, Sjoerd Klarenbeek, Cheei-Sing Hau, Daphne Kaldenbach, Elisabeth A.M. Raeven, Kim Vrijland, Marleen Kok, Karin E. de Visser
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Breast cancer metastasis
myeloid cells
neoadjuvant immune checkpoint blockade
regulatory T cells
resistance mechanisms
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2201147
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2201147

Similar Items